Seeking Alpha

Durect (DRRX) submits NDA for POSIDUR, a non-opioid, long-acting local anesthetic for the...

Durect (DRRX) submits NDA for POSIDUR, a non-opioid, long-acting local anesthetic for the treatment of post-surgical pain. The company, which is also developing an abuse-resistant form of oxycodone, notes that non-opioid options for the management of pain post-surgery can hasten recovery and shorten hospital stays.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs